SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility and intense community speculation, driven by the massive concentration of high-bandwidth memory giants like Samsung and SK Hynix within its index. Traders are actively debating whether the current price action represents a sustainable super-cycle driven by AI chip demand or a dangerously overextended, leverage-fueled bubble prone to rapid sell-offs.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure following media reports that it may be exploring a significant equity raise to support its massive AI infrastructure and data center capital expenditure requirements. Investors are debating whether this potential dilution signifies a long-term strategic commitment to AI dominance or a sign of unsustainable spending, leaving the stock caught between concerns over shareholder impact and its core advertising business performance.

Leidos Holdings, Inc. engages in providing services and solutions in the defense, intelligence, civil and health markets. It operates through the following three segments: Defense Solutions, Civil, and Health. The Defense Solutions segment provides services, solutions, and products focusing on digital modernization, mission systems and integration, command, control, computers, communications, intelligence, surveillance and reconnaissance technologies and services, maritime solutions, transformative software, analytics, intelligence analysis, mission support and logistics services, weapons systems and space systems and solutions. The Civil segment focuses on modernizing infrastructure, systems, and security. The Health segment offers solutions to federal and commercial customers that are responsible for the health and wellbeing of people worldwide including service members and veterans. The company was founded by John Robert Beyster on February 3, 1969 and is headquartered in Reston, VA.

Leidos Holdings Inc

Leidos Holdings is currently in the spotlight as investors track its strong performance across defense and digital modernization, underscored by a steady stream of high-value government contracts. The community is actively debating its valuation compared to peers and focusing on the company's expanding footprint in AI-driven security and defense infrastructure.

TON (The Open Network) is a general-purpose&nbsp;blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is attracting significant community attention as investors weigh the impact of its deep integration with the Telegram ecosystem against recent market volatility and technical resistance. While some traders are focused on the growth of Ton-based wallet activity and new institutional listings, others are debating the sustainability of current price levels amid ongoing concerns regarding token unlocks and structural market shifts.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

The ProShares Bitcoin Strategy ETF is trending as investors grapple with its ongoing price volatility alongside broader market fluctuations in Bitcoin. Community discussion is heavily focused on the contrast between the ETF's consistent monthly dividend payouts and the NAV decay, with many debating whether to hold for income or shift into spot Bitcoin products.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing extreme downward pressure, with community members expressing panic and frustration as the token hits multi-year lows. Many investors are debating whether these levels represent a rare buying opportunity or a signal of deeper structural failure, with sentiment largely split between those aggressively averaging down and those who believe the crypto sector is facing a terminal decline.

Ethereum Classic

Ethereum Classic is trending as frustrated investors debate its long-term viability against other major assets, with many expressing deep disappointment over stagnant price action. The community remains polarized, frequently comparing the token's current performance to its historical highs while split between those liquidating out of exhaustion and others doubling down in anticipation of a potential altcoin rally.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing significant market volatility as investors focus on the promising data from its late-stage study on paridiprubart for acute kidney injury. Community discussion is heavily divided between those anticipating a major partnership or acquisition based on the drug's potential and skeptics warning of potential dilution or management's historical lack of clear communication.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing intense investor interest as the April 30th PDUFA date for the Auvelity label expansion into Alzheimer's agitation approaches, with analysts increasingly confident in an approval. Community sentiment remains bullish, highlighting the drug's potential as a first-in-class treatment for an underserved market and viewing recent stock volatility as a buying opportunity ahead of anticipated regulatory success and upcoming earnings.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through North America and International Personal Care segments. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Dallas, TX.

Kimberly-Clark Corp.

Kimberly-Clark is currently trending due to a combination of aggressive insider buying and a rotation into defensive consumer staples as investors look for stable dividends amid broader market volatility. Community members are actively debating the long-term impact of the Kenvue acquisition and whether the current price levels represent a significant value opportunity or a persistent trap driven by ongoing litigation concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a leader in the sector announced a partnership with another micro-cap biotech company to further advance its development efforts in the space. Investors responded positively to the news, sending shares of both companies sharply higher following the announcement.PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) announced that it has signed a term sheet with Jupiter Neurosciences, Inc. (NASDAQ: JUNS) to grant the company exclusive perpetual U.S. ...

PharmAla Biotech Holdings, Inc. is a biotechnology company, which engages in the research, development, and manufacturing of MDXX class molecules, including MDMA. It also provides manufacturing of active pharmaceutical ingredient (API) and drug product formulation. The company was founded on January 12, 2021 and is headquartered in Toronto, Canada.

Current Price	$0.1198
Prev Close	$0.1106
Open	$0.1154
Dividend Yield	0.00%
50-Day Moving Average	$0.0988
Beta	0.00
Avg. Volume	26,454.25
PE Ratio	-10.89

52-Week High	$0.1511
52-Week Low	$0.0614
Market Capitalization	$13.04M
EPS (Annual)	-$0.0156
Price to Book	8.25
Revenue Per Employee	N/A

MDXXFPharmAla Biotech Holdings Inc.

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest MDXXF News